The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2012Phase I-B Clinical Trial of AVE8112 for Cognitive Impairment in Parkinson’s Disease
Objective/Rationale:
Cognitive impairment is a symptom seen in Parkinson’s disease (PD) patients, and some can progress to dementia. AVE8112 is a PDE4 inhibitor that was in development by the... -
Target Validation, 2012Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease
Objective/Rationale:
Parkinson’s disease (PD) involves inappropriate activation of the immune system. Cytokines activate immune cells by engaging the JAK/STAT pathway, which receives signals from... -
MJFF Research Grant, 2012The Role of Amyloid in the Progression of Cognitive Impairment in PD: A Prospective Cohort Study
Objective/Rationale:
Dementia is a frequent and devastating non-motor complication of Parkinson's disease (PD). Although loss of dopamine producing brain cells play a role in cognitive... -
Target Validation, 2012Evaluation of the Microtubule-Stabilizing Agent, Epothilone D, in Mouse Models of Parkinson's Disease
Objective/Rationale:
Microtubules are critical components within nerve cells, where they serve as the “railroad” tracks upon which cellular cargo is transported up and down the length of... -
Biomarker Development, 2012The Fox Investigation for New Discovery of Biomarkers (BioFIND)
Objective/Rationale:
Biomarkers — a biological marker of disease presence or risk like cholesterol level for heart disease — will greatly aid clinicians’ ability to diagnose Parkinson’s... -
Therapeutics Development Initiative, 2012Anti-parkinsonian and Anti-dyskinetic Efficacy of HE3286 in a Model of Parkinson’s Disease
Objective/Rationale:
HE3286 is an anti-inflammatory drug in phase II clinical trials for other diseases that is being evaluated for treatment of Parkinson’s disease (PD). HE3286 taken orally rapidly...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.